Vycor Medical, Inc. reported financial results for the year ended December 31, 2025, showing substantial growth in its core neurosurgical business and important clinical validation for its developing vision therapy division. The company's performance highlights the increasing global adoption of its technologies and aligns with healthcare's shift toward digital and minimally invasive treatments.
The Vycor Medical division, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgeons, saw revenues increase by 18% to $1,796,070, with most growth coming from international markets. This international expansion represents a key company strategy, though sales growth continued in the United States. The company reported an operating profit of $33,900, a significant improvement from an operating loss of $9,145 in 2024. On a non-GAAP basis, which excludes non-cash items like depreciation and stock-based compensation, operating profit was $145,881 compared to $81,548 in 2024.
Clinical validation played a crucial role in the company's 2025 performance. Seven new peer-reviewed studies on the VBAS were published, bringing the total to 50 peer-reviewed clinical papers, with an additional 14 other clinical papers. These studies originated from multiple countries, including the United States, United Kingdom, Japan, and Mexico, highlighting the system's international clinical footprint. The research consistently demonstrates the VBAS's advantages in reducing brain tissue damage, improving patient outcomes, and reducing hospital stays. For an overview of the VBAS system, see https://www.vycormedical.com.
Equally significant was a 2025 clinical study on NovaVision's NeuroEyeCoach therapy program, which compared home-based use with clinic-based use. The study concluded that both settings produced meaningful improvements in patients' activities of daily living, with no significant differences between them. This validation of remote effectiveness is particularly important given global healthcare systems' push toward digital home-based technologies. The NovaVision division, which remains in development, focuses on therapy programs for visual disorders after stroke or brain injury. For more information on NovaVision, visit https://www.novavision.com.
Financially, total company revenue reached $1,863,400, a 17% increase over 2024. Gross profit was $1,498,295, an 11% increase, though the gross margin decreased to 83% from 89% due to validation costs, shipping, higher manufacturing costs for new production, and a higher mix of international sales. The NovaVision division generated $67,330 in revenue with a 93% gross margin. On a GAAP basis, the company reported a net loss of $396,796, or $0.01 per share, which includes preferred stock dividends. The non-GAAP net loss was $284,815, also $0.01 per share.
The company's transition to profitability in its core operations, combined with strong clinical validation across both business units, demonstrates its potential in growing medical technology markets. The international success of VBAS and the proven effectiveness of remote NeuroEyeCoach therapy position Vycor Medical to benefit from two major healthcare trends: the globalization of medical device adoption and the expansion of digital therapeutic solutions into home settings.
